Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Trader J who wrote (9207)	11/7/1998 1:20:00 AM
From: DavidCG	Respond to of 119973

AVII : gene therapy/vaccines/antisense for cancer.. Phase III human testing for one cancer (colorectal (colon) cancer) about to begin with 300 patients. Phase II human testing for two other cancer vaccines. (prostate and pancreatic). Phase I human testing for two other antisense cancer drugs. One Drug delivery technology with potential for MANY drugs. Currently in FIVE clinical human studies. AVII has over 27 patents! Of those..look at this one: "This basket of technology includes one issued patent and one provisional patent application describing the use of telomere mimics for the treatment of cancer and other diseases. Telomeres are DNA sequences on the ends of chromosomes that define the age of a cell. Cancer cells are ageless or immortal due to their ability to reset the telomere-aging clock. This synthetic oligonucleotide strategy interferes with the system of communication between the telomere and the aging process in cancer cells, resulting in rapid and selective cancer cell death. The telomere communication system may also be involved in a variety of chronic diseases including rheumatoid arthritis." Remind you of GERN? ENMD? Antisense, Gene Therapy, Cancer Vaccines, Drug delivery, Telomeres All wrapped into one company trading at a fraction of where it should be? antivirals.com Trading at $4.00 a share, Only 11 mil Outstanding, and 6.3 mil float. -DavidCG AVI BioPharma Inc. is dedicated to the development and commercialization of products for the treatment of life-threatening diseases using three platform technologies: immunotherapy for cancer, gene-targeted drugs and intracellular drug delivery engines. Its lead clinical agent, Avicine(tm), an essentially non-toxic cancer vaccine, will soon enter a Phase III licensing trial in colorectal cancer, a Phase II/III trial in pancreatic cancer and a Phase II trial in prostate cancer. The Company has also developed a patented class of gene-targeted drugs, called NeuGenes(R), which may be useful in the treatment of a wide range of human diseases including cardiovascular restenosis and cancer. Further, AVI has developed a novel drug delivery technology, called CytoPorter(tm), that may be useful in significantly improving drug uptake while minimizing toxicity for a wide range of FDA approved drugs.